Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zeng, Yuhong
NCT05884372: Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.	Recruiting	4	100	RoW	Eldecalcitol, Native Vitamin D, Denosumab, Calcium	Xi'an Honghui Hospital, Chugai Pharma China Co., Ltd.	Osteoporosis in Postmenopausal Women	12/24	06/25
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Recruiting	4	300	RoW	Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei	Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd.	Low Bone Mineral Density, Postmenopausal Osteoporosis	06/25	12/25
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture	Completed	3	514	RoW	HLX14, Prolia®	Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.	Postmenopausal	12/23	07/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zeng, Yuhong
NCT05884372: Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.	Recruiting	4	100	RoW	Eldecalcitol, Native Vitamin D, Denosumab, Calcium	Xi'an Honghui Hospital, Chugai Pharma China Co., Ltd.	Osteoporosis in Postmenopausal Women	12/24	06/25
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Recruiting	4	300	RoW	Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei	Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd.	Low Bone Mineral Density, Postmenopausal Osteoporosis	06/25	12/25
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture	Completed	3	514	RoW	HLX14, Prolia®	Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.	Postmenopausal	12/23	07/24